SEC Filing Summary: ChromaDex Corp. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ChromaDex Corp. on February 14, 2012, covering events occurring on February 10, 2012. The filing details the consummation of two separate equity financing transactions: a private placement and a registered direct offering. Note: The input metadata references "Niagen Bioscience, Inc.," but the filing text explicitly identifies the registrant as ChromaDex Corp.
Key Financial Metrics and Capital Raised
- Private Placement Proceeds: Approximately $3,700,000 gross proceeds from the sale of 4,933,329 shares at $0.75 per share.
- Registered Direct Offering Proceeds: $7,500,000 gross proceeds from the sale of 9,966,666 shares at $0.75 per share.
- Total Capital Raised: Approximately $11,200,000 in aggregate gross proceeds from both transactions.
- Transaction Costs: $259,000 paid to Aegis Capital Corp. for the private placement; $525,000 paid in commissions and expenses for the registered offering.
- Warrants Issued: 300,000 warrants issued to the placement agent for the registered offering.
- Revenue, Profit, and Cash Flow: The filing text does not provide specific values for revenue, net income, operating cash flow, or debt levels.
Material Changes and Transaction Details
The primary material change is the significant increase in share count and cash liquidity resulting from the two offerings consummated in early February 2012. The private placement was completed on February 10, 2012, involving accredited investors including company management. The registered direct offering was completed on February 9, 2012. Both transactions were executed at a price of $0.75 per share.
Outlook, Risks, and Management Commentary
The filing includes standard forward-looking statements regarding plans and strategies, noting that these are subject to uncertainties. A specific risk highlighted is the need to secure capital for general working purposes. The company disclaims any obligation to update forward-looking statements. No specific guidance on future revenue or earnings is provided in this text.
Key Facts for Investor Verification
- Verify the total number of outstanding shares post-transaction to assess dilution impact.
- Confirm the use of proceeds for the $11.2 million raised, specifically regarding working capital needs.
- Review the terms of the 300,000 warrants issued to the placement agent, including exercise price and expiration.
- Check subsequent filings for the impact of these capital raises on the company's cash position and runway.